By admin 
The study, a culmination of a decade of meticulous research spanning human trials, animal models, and extensive clinical data analysis, pinpoints genetic variations in the enzyme PAM (peptidyl-glycine alpha-amidating monooxygenase) as a key factor in this resistance. Approximately 10% of the global population carries these particular genetic variants. For these individuals, the efficacy of GLP-1 receptor agonists, which include popular medications like Ozempic, Wegovy, Rybelsus, Victoza, and Trulicity, appears to be diminished when it comes to blood sugar control. This finding carries substantial implications, especially given the rapid expansion of these drugs beyond Type 2 diabetes into the treatment of obesity, where they are often prescribed at even higher doses.
GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced in the gut in response to food intake. Its physiological roles are multifaceted and critical for metabolic health. GLP-1 stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it only prompts insulin release when blood sugar levels are high, thereby reducing the risk of hypoglycemia. It also suppresses glucagon secretion from pancreatic alpha cells, which helps lower hepatic glucose production. Furthermore, GLP-1 slows gastric emptying, leading to increased satiety and reduced food intake, and has direct effects on the brain to suppress appetite. These combined actions make GLP-1 a powerful regulator of blood glucose and body weight. GLP-1 receptor agonists are synthetic versions or analogues of natural GLP-1, designed to bind to and activate the GLP-1 receptor, thereby mimicking and often enhancing these beneficial effects, but with a longer duration of action in the body. The global market for these drugs has exploded, driven by their impressive efficacy in both diabetes management and weight loss, making them some of the best-selling pharmaceuticals worldwide.
The research, published on March 29 in Genome Medicine, focused primarily on the drugs’ impact on blood sugar regulation. Dr. Anna Gloyn, DPhil, a professor of pediatrics and genetics at Stanford and one of the study’s senior authors, emphasized the clinical relevance of their findings. "In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment," Gloyn noted. She highlighted that identifying non-responders early could significantly improve patient care, enabling clinicians to switch patients to more effective treatments sooner rather than later. This aligns perfectly with the burgeoning field of precision medicine, which aims to tailor medical treatment to each patient’s unique genetic makeup, environment, and lifestyle.
The collaborative effort was led by a distinguished team of researchers. Alongside Dr. Gloyn, Dr. Markus Stoffel, MD, PhD, professor of metabolic diseases at the Institute of Molecular Health Sciences, ETH Zurich in Switzerland, served as a senior author. The lead authors were Dr. Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Gloyn, and Dr. Elisa Araldi, PhD, associate professor of medicine and surgery at the University of Parma in Italy and a former trainee with Stoffel. Dr. Umapathysivam articulated the practical challenges that motivated this research: "When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically." He added that this study represents "the first step in being able to use someone’s genetic make-up to help us improve that decision-making process."
Despite the significant strides made in identifying the genetic link to GLP-1 resistance, the precise underlying biological mechanism remains an elusive "million-dollar question," as Dr. Gloyn put it. The team meticulously investigated numerous potential pathways for resistance but has yet to definitively pinpoint the exact molecular defect. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we’ve done, we’ve not been able to nail precisely why they are resistant," she explained, underscoring the complexity of the biological puzzle.
The core of the research focused on two specific genetic variants, p.S539W and p.D563G, which impact the PAM enzyme. PAM is a truly unique and critical enzyme because it is the only enzyme in the human body capable of performing a chemical process called amidation. Amidation is a post-translational modification where a glycine residue at the C-terminus of a peptide is converted into an amide. This process is essential for activating and increasing the half-life or potency of a vast array of biologically active peptides and hormones, including GLP-1, calcitonin, vasopressin, and oxytocin. "We thought, if you have a problem with this enzyme, there’s going to be multiple aspects of your biology that are not working properly," Gloyn explained, highlighting the enzyme’s widespread importance.
Prior research had already established a link between PAM variants and an increased susceptibility to diabetes, as well as impaired insulin release from the pancreas. Building on this knowledge, the team hypothesized that these variants might also disrupt the normal function of GLP-1. To test this, researchers conducted detailed studies on adults both with and without the p.S539W PAM variant. Participants consumed a sugary solution, and their blood glucose and hormone levels were monitored meticulously every five minutes over a four-hour period. Notably, participants in this phase of the study did not have diabetes, to avoid confounding variables introduced by the disease itself.
The initial expectation was that individuals with the PAM variant would exhibit lower circulating GLP-1 levels, perhaps due to impaired processing or stability of the hormone. However, the results were strikingly contrary to this hypothesis. "What we actually saw was they had increased levels of GLP-1," Gloyn revealed. "This was the opposite of what we imagined we would find." This unexpected observation immediately signaled a novel form of resistance. Despite these elevated GLP-1 levels, the individuals with the PAM variant showed no corresponding improvement in blood sugar regulation. "Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity. They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1," Gloyn clarified.
Given the surprising nature of these findings, the research team embarked on a multi-year effort to rigorously verify their observations using diverse experimental approaches. "We couldn’t understand this, which is why we looked as many different ways as we could to see if this was a really robust observation," Gloyn recounted. This included collaborating with scientists in Zurich who were studying mice genetically engineered to lack the PAM gene. These PAM-deficient mice strikingly mirrored the human observations, displaying signs of GLP-1 resistance coupled with elevated GLP-1 levels that failed to translate into improved blood sugar control.
Further investigations in these mouse models shed more light on the functional consequences of PAM deficiency. One of GLP-1’s crucial roles is to slow gastric emptying, a mechanism that helps regulate post-meal blood sugar spikes and contributes to satiety and weight loss. In mice lacking the PAM gene, food passed through the stomach more rapidly. Crucially, treatment with GLP-1 receptor agonists failed to effectively slow this gastric transit, indicating a direct impairment in GLP-1 responsiveness at a physiological level. The researchers also observed reduced responsiveness to GLP-1 in both the pancreas and the gut of these mice, despite finding no changes in the number of GLP-1 receptors in these tissues. This suggested that the problem wasn’t a lack of "landing sites" for GLP-1, but rather a defect further down the signaling pathway. Additional experiments with collaborators in Copenhagen further confirmed that the PAM defect does not impede GLP-1’s ability to bind to its receptor or to initiate signal transmission, reinforcing the idea that the resistance manifests at a post-receptor level, affecting downstream cellular responses.
To translate these mechanistic insights into clinical relevance, the team meticulously analyzed data from several clinical trials involving individuals with Type 2 diabetes. A combined analysis of three separate trials, encompassing 1,119 participants, provided compelling evidence. Individuals carrying the PAM variants responded less effectively to GLP-1 receptor agonists and were significantly less likely to achieve their target HbA1c levels – a critical measure of long-term blood sugar control. Specifically, after six months of GLP-1 treatment, approximately 25% of participants without the PAM variants reached the recommended HbA1c target. In stark contrast, only 11.5% of those with the p.S539W variant and 18.5% of those with the p.D563G variant achieved this goal.
A crucial aspect of these findings was the specificity of the GLP-1 resistance. The genetic variants in PAM did not affect how patients responded to other commonly prescribed diabetes medications, including sulfonylureas, metformin, and DPP-4 inhibitors. "What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications," Gloyn emphasized. "We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology." This specificity strongly supports the direct link between the PAM variants, GLP-1 processing, and the efficacy of GLP-1-based therapies.
Interestingly, two additional clinical trials, funded by pharmaceutical companies, showed no significant difference in GLP-1 drug response between carriers and non-carriers of the PAM variants. Dr. Gloyn speculated that this discrepancy might be attributable to the use of longer-acting GLP-1 formulations in these trials. It’s plausible that these extended-release versions, by providing a more sustained and consistent stimulation of the GLP-1 receptor, might be able to partially overcome the inherent GLP-1 resistance observed in individuals with PAM variants. This opens a potential avenue for tailoring treatment strategies, suggesting that longer-acting GLP-1 RAs might be a more suitable option for patients identified with these genetic predispositions.
The journey to understand GLP-1 resistance began nearly a decade ago, predating the widespread use of GLP-1 drugs for weight loss. Consequently, only two of the analyzed trials included detailed weight data, and these showed no clear difference in weight loss outcomes between individuals with and without PAM variants. However, this limited dataset is not definitive, and further research is critically needed to understand the impact of GLP-1 resistance on the increasingly prevalent use of these drugs for obesity treatment.
A significant hurdle in advancing this research is the challenge of accessing comprehensive genetic data from ongoing and completed clinical trials. "It’s very common for pharmaceutical companies to collect genetic data on their participants," Gloyn stated. She advocated for greater transparency and data sharing, particularly for newer GLP-1 medications, to help researchers identify genetic markers that could predict poor responders. Such collaborative efforts could accelerate the development of personalized treatment algorithms.
The biological cause of GLP-1 resistance remains a complex and multifaceted enigma. Dr. Gloyn drew a parallel to insulin resistance, a phenomenon that scientists have studied for decades and still do not fully comprehend, yet effective treatments have been developed. This perspective offers both humility regarding the unknown and optimism for future solutions. "There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance," she mused.
This monumental study was a testament to international scientific collaboration, with contributions from researchers at the University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath, and University of Exeter. The work received substantial funding from prestigious organizations including Wellcome, the Medical Research Council, the European Union Horizon 2020 Programme, the National Institutes of Health, the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim, and Diabetes Australia, underscoring the broad scientific interest and investment in unraveling the complexities of metabolic disease.
In conclusion, this landmark research not only sheds critical light on a genetic predisposition to GLP-1 resistance but also paves the way for a more personalized approach to treating Type 2 diabetes and potentially obesity. By identifying individuals who may not respond optimally to GLP-1 receptor agonists, clinicians could proactively select alternative therapies or tailored formulations, thereby optimizing treatment outcomes, reducing healthcare costs associated with ineffective medications, and significantly improving the quality of life for millions worldwide. The ongoing quest to fully understand the intricate biology of GLP-1 resistance will undoubtedly continue to drive innovation in metabolic medicine.